OptimizeRx Corp. (NASDAQ:OPRX) Receives $11.81 Average PT from Brokerages

OptimizeRx Corp. (NASDAQ:OPRX) has received an average rating of “Moderate Buy” from the twelve ratings firms that are covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $11.8125.

Several research analysts recently issued reports on the stock. Zacks Research raised shares of OptimizeRx from a “hold” rating to a “strong-buy” rating in a research note on Friday, September 5th. Stifel Nicolaus upped their price objective on shares of OptimizeRx from $16.00 to $18.00 and gave the company a “buy” rating in a report on Friday, August 8th. JMP Securities raised their target price on OptimizeRx from $14.00 to $20.00 and gave the company a “market outperform” rating in a research note on Monday, August 11th. Roth Capital reaffirmed a “buy” rating on shares of OptimizeRx in a research report on Friday, August 8th. Finally, Wall Street Zen upgraded OptimizeRx from a “hold” rating to a “buy” rating in a report on Thursday, May 22nd.

Insider Buying and Selling

In other OptimizeRx news, Director Patrick D. Spangler sold 11,120 shares of the firm’s stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $17.49, for a total transaction of $194,488.80. Following the transaction, the director directly owned 44,215 shares in the company, valued at approximately $773,320.35. This trade represents a 20.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 5.60% of the company’s stock.

Institutional Trading of OptimizeRx

Several institutional investors have recently made changes to their positions in OPRX. American Century Companies Inc. raised its holdings in shares of OptimizeRx by 9.6% in the first quarter. American Century Companies Inc. now owns 15,783 shares of the company’s stock valued at $137,000 after purchasing an additional 1,387 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in OptimizeRx by 600.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock worth $29,000 after purchasing an additional 1,818 shares during the last quarter. Bank of New York Mellon Corp grew its position in OptimizeRx by 2.1% in the 1st quarter. Bank of New York Mellon Corp now owns 89,538 shares of the company’s stock worth $775,000 after purchasing an additional 1,826 shares in the last quarter. BNP Paribas Financial Markets grew its position in OptimizeRx by 119.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after purchasing an additional 2,215 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in OptimizeRx by 10.5% in the 1st quarter. Rhumbline Advisers now owns 27,785 shares of the company’s stock valued at $241,000 after buying an additional 2,636 shares during the last quarter. Institutional investors own 76.47% of the company’s stock.

OptimizeRx Price Performance

OptimizeRx stock opened at $17.33 on Wednesday. The stock has a market capitalization of $321.73 million, a price-to-earnings ratio of -32.09 and a beta of 1.20. OptimizeRx has a 52-week low of $3.78 and a 52-week high of $19.25. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.57 and a current ratio of 2.57. The stock’s 50 day moving average price is $15.36 and its two-hundred day moving average price is $11.83.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.